Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cell therapy trial hopes to tame multiple sclerosis

NCT ID NCT07008378

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 35 times

Summary

This early-stage study tests a new treatment called P-CD19CD20-ALLO1 in 60 adults with multiple sclerosis (MS). The treatment uses specially engineered immune cells to target and possibly calm the immune attack on the nervous system. The main goal is to check safety and side effects, not yet to prove it works as a cure. Participants must be 18-60 years old and have either progressive or relapsing MS.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Multiple Sclerosis Comprehensive Care Center at Northwell Health

    New York, New York, 10075, United States

  • Rutgers University- Robert Wood Johnson Medical School

    New Brunswick, New Jersey, 08901-1962, United States

  • UCI Sue & Bill Gross Stem Cell Research Center

    Irvine, California, 92697, United States

  • UCSD Altman Clinical and Translational Research Institute

    La Jolla, California, 92037-1337, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110-1010, United States

Conditions

Explore the condition pages connected to this study.